腫瘍溶解ウイルス療法市場- 世界の産業規模、動向、機会、予測、ウイルスタイプ別、用途別、エンドユーザー別、地域別、競合別、2019年～2029年

世界の腫瘍溶解ウイルス療法市場は、2023年に2,122万米ドルと評価され、2029年までのCAGRは20.14%で、予測期間中に力強い成長を予測しています。

世界のがん溶解性ウイルス療法市場は、近年著しい成長と進歩を遂げ、がん治療の変革期を迎えています。最先端のアプローチである腫瘍溶解ウイルス療法は、ウイルスを利用して健康な細胞を温存しながらがん細胞を選択的に標的にして破壊します。この革新的な治療法は、腫瘍学分野における有望な手段として勢いを増しています。この市場の成長は、世界中で様々な種類のがんの有病率が増加し、新規で効果的な治療介入に対する需要が高まっていることに起因しています。世界の腫瘍溶解ウイルス療法市場を推進している主な要因の1つは、腫瘍溶解ウイルスの設計と最適化に焦点を当てた広範な研究開発活動です。これらのウイルスは、しばしばがん標的能力を強化するために改変され、腫瘍細胞内で特異的に複製するように設計され、腫瘍細胞の破壊につながります。さらに、腫瘍溶解ウイルス療法の研究開発を推進するために、専門知識やリソースを結集することを目的とした、製薬企業、研究機関、バイオテクノロジー企業間の戦略的提携や共同研究が急増しています。さらに、医療従事者や患者の間で、腫瘍溶解ウイルス療法の潜在的な利点に対する認識が高まっていることも、市場の拡大に寄与しています。さまざまながんの治療におけるオンコリティック・ウイルスの安全性と有効性が実証される臨床試験が増えるにつれ、医療界ではこの治療法の受容と採用が進んでいます。また、ヘルスケア・インフラへの投資の増加や、革新的ながん治療法を最前線に送り出すための継続的な努力も市場を後押ししています。結論として、世界の腫瘍溶解ウイルス療法市場は、研究開発の進展、戦略的提携、がんの有病率の増加などを原動力として、大幅な成長を遂げようとしています。腫瘍溶解ウイルス療法は臨床試験で有望視され続けており、がん治療に革命をもたらし、世界規模で患者の転帰を改善する可能性を秘めています。

市場促進要因

がん罹患率の増加

研究開発の進展

ヘルスケアインフラへの投資

主な市場課題

がん生物学の複雑性

免疫原性と免疫反応

主要市場動向

個別化医療への注力

臨床の進歩

セグメント別の洞察

ウイルスタイプ別の洞察

用途別の洞察

地域別の洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 腫瘍溶解ウイルス療法の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • ウイルスタイプ別（遺伝子組換え腫瘍溶解ウイルス、野生型腫瘍溶解ウイルス）
  • 用途別（肺がん、乳がん、大腸がん、メラノーマ、前立腺がん、頭頸部がん、卵巣がん、膵臓がん、その他）
  • エンドユーザー別（病院・クリニック、がん研究センター、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • ウイルスタイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 アジア太平洋地域の腫瘍溶解ウイルス療法市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • ウイルスタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の腫瘍溶解ウイルス療法市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • ウイルスタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の腫瘍溶解ウイルス療法市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • ウイルスタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の腫瘍溶解ウイルス療法市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • ウイルスタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの腫瘍溶解ウイルス療法市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • ウイルスタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 腫瘍溶解ウイルス療法の世界市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Immunocore Holdings plc
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Oncolytic Virotherapy Market was valued at USD 21.22 Million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 20.14% through 2029. The Global Oncolytic Virotherapy Market has witnessed significant growth and advancements in recent years, marking a transformative era in cancer treatment. Oncolytic virotherapy, a cutting-edge approach, utilizes viruses to selectively target and destroy cancer cells while sparing healthy ones. This innovative treatment method has gained momentum as a promising avenue in the field of oncology. The market's growth can be attributed to the increasing prevalence of various cancer types worldwide, driving the demand for novel and effective therapeutic interventions. One of the key factors propelling the Global Oncolytic Virotherapy Market is the extensive research and development activities focused on designing and optimizing oncolytic viruses. These viruses, often modified for enhanced cancer-targeting capabilities, are engineered to replicate specifically within tumor cells, leading to their destruction. Additionally, the market has witnessed a surge in strategic collaborations and partnerships between pharmaceutical companies, research institutions, and biotechnology firms, aiming to leverage collective expertise and resources to advance oncolytic virotherapy research and development. Moreover, the rising awareness about the potential benefits of oncolytic virotherapy among healthcare professionals and patients has contributed to the market's expansion. As more clinical trials demonstrate the safety and efficacy of oncolytic viruses in treating various cancers, there is a growing acceptance and adoption of this therapy in the medical community. The market is also fueled by the increasing investment in healthcare infrastructure and the continuous efforts to bring innovative cancer therapies to the forefront. In conclusion, the Global Oncolytic Virotherapy Market is poised for substantial growth, driven by advancements in research and development, strategic collaborations, and the increasing prevalence of cancer. As oncolytic virotherapy continues to show promise in clinical trials, it holds the potential to revolutionize cancer treatment and improve patient outcomes on a global scale.

Key Market Drivers

Increasing Incidence of Cancer

The escalating incidence of cancer globally serves as a pivotal driver for the burgeoning Global Oncolytic Virotherapy Market. Over the past few decades, the prevalence of various cancer types has witnessed an alarming rise, necessitating the exploration of innovative and targeted therapeutic strategies. Oncolytic virotherapy has emerged as a promising approach in this landscape, offering a unique solution to combat cancer by leveraging modified viruses to selectively target and destroy malignant cells. The increasing burden of cancer, characterized by factors such as lifestyle changes, environmental exposures, and an aging population, underscores the urgent need for alternative and effective treatment modalities. Oncolytic virotherapy, with its ability to specifically replicate within cancer cells, while sparing healthy tissues, aligns with the demand for precision medicine in oncology. As the incidence of cancer continues to surge globally, oncolytic virotherapy presents a ray of hope in the quest for more potent and targeted cancer treatments. The market's growth is intricately linked to the pressing healthcare challenge posed by the rising number of cancer cases, driving research, development, and investment in oncolytic virotherapy as a viable and innovative therapeutic option. The increasing recognition of the potential benefits of oncolytic virotherapy, coupled with a growing understanding of its mechanisms, positions it as a transformative force in the evolving landscape of cancer care.

Advancements in Research and Development

Advancements in research and development (R&D) play a pivotal role in propelling the Global Oncolytic Virotherapy Market to the forefront of innovative cancer treatments. The dynamic landscape of virology, molecular biology, and genetic engineering has witnessed remarkable progress, fostering the design and optimization of oncolytic viruses. Researchers are continually pushing boundaries, developing novel viral vectors with enhanced cancer-targeting capabilities, improved safety profiles, and increased therapeutic efficacy. These advancements are not only instrumental in expanding the repertoire of oncolytic viruses but also contribute to the overall understanding of the complex interactions between viruses and cancer cells. The ongoing R&D efforts are marked by a commitment to overcoming challenges and refining oncolytic virotherapy's mechanisms of action. Scientists are engaged in exploring various viral platforms, optimizing delivery methods, and tailoring viruses to specific cancer types, paving the way for personalized and precise treatments. The continuous refinement of oncolytic virotherapy protocols through preclinical and clinical trials showcases the commitment to safety, efficacy, and therapeutic optimization. The synergy between technological breakthroughs and research endeavors is driving the evolution of oncolytic virotherapy as a viable and potent treatment option. As R&D activities yield promising results, they not only contribute to the expansion of the therapeutic arsenal but also attract increased investments and collaborations within the pharmaceutical and biotechnology sectors. Ultimately, the advancements in research and development form the bedrock of the Global Oncolytic Virotherapy Market, positioning it as a dynamic and transformative force in the realm of cancer therapeutics.

Investments in Healthcare Infrastructure

Investments in healthcare infrastructure are pivotal to the growth and development of the Global Oncolytic Virotherapy Market. Governments, private institutions, and investors globally are recognizing the potential of oncolytic virotherapy as a groundbreaking approach to cancer treatment. Substantial financial support directed towards healthcare infrastructure, research facilities, and clinical trial capabilities serves as a catalyst for advancing the field. The funds allocated to infrastructure development not only enhance the research and development capabilities of institutions but also enable the establishment of state-of-the-art facilities for the production, testing, and administration of oncolytic virotherapy. The strategic allocation of resources fosters collaborations between academia, industry, and healthcare organizations, creating synergies that accelerate the translation of scientific discoveries into clinical applications. Investments in specialized equipment, cleanroom facilities, and bioprocessing technologies contribute to the scalability and commercial viability of oncolytic virotherapy products. Moreover, the financial backing supports the training and education of professionals in the field, ensuring a skilled workforce capable of navigating the complexities of oncolytic virotherapy research and implementation. As healthcare infrastructure continues to evolve, the Global Oncolytic Virotherapy Market benefits from enhanced capabilities to conduct rigorous clinical trials, adhere to regulatory standards, and seamlessly integrate innovative therapies into mainstream medical practice. The commitment to robust healthcare infrastructure reflects a broader acknowledgment of the transformative potential of oncolytic virotherapy, positioning it as a key player in the evolving landscape of cancer treatment.

Key Market Challenges

Complexity of Cancer Biology

The complexity of cancer biology stands as a formidable challenge in the context of the Global Oncolytic Virotherapy Market. Cancer, characterized by its heterogeneity and the intricate interplay of genetic, molecular, and environmental factors, presents a multifaceted obstacle for oncolytic virotherapy. Designing viruses that can effectively target a diverse array of cancer types, each with its unique genetic makeup and microenvironment, requires a nuanced understanding of the intricate biology at play. The variability in tumor characteristics among patients demands a level of adaptability and customization in oncolytic virotherapy approaches, making it challenging to develop universally applicable treatments. Moreover, the dynamic nature of cancer progression, the potential for tumor evolution, and the development of resistance mechanisms further complicate the therapeutic landscape. Oncolytic viruses must not only navigate the complexities of the primary tumor but also address the challenges posed by metastatic lesions. This necessitates continuous innovation and the development of oncolytic viruses capable of adapting to the evolving nature of cancer biology. Researchers face the task of deciphering the intricate signaling pathways, immune evasion mechanisms, and the heterogeneity within tumors to optimize the design and delivery of oncolytic virotherapy. Overcoming the challenges posed by the complexity of cancer biology is paramount for the successful development and application of oncolytic viruses, positioning them as effective and adaptable weapons in the ongoing battle against cancer. The integration of cutting-edge research and technological advancements is crucial to unraveling the intricacies of cancer biology and harnessing its insights for the advancement of oncolytic virotherapy.

Immunogenicity and Immune Response

Immunogenicity and immune response present significant challenges within the Global Oncolytic Virotherapy Market. While oncolytic virotherapy leverages viruses to selectively target cancer cells, the immune system's complex response to these viral vectors can influence treatment outcomes. The immunogenicity of oncolytic viruses, referring to their potential to trigger an immune response, can lead to the development of anti-viral antibodies, limiting the therapeutic efficacy and duration of treatment. Additionally, the host immune system may recognize and clear oncolytic viruses before they can effectively reach and destroy cancer cells. Balancing the delicate interplay between oncolytic virotherapy and the immune system is crucial for optimizing treatment outcomes. On one hand, a robust immune response is desirable to enhance the therapeutic effect by promoting anti-tumor immunity. On the other hand, an overly aggressive immune response may result in premature clearance of the oncolytic viruses or neutralization of their effects, compromising their ability to target and destroy cancer cells. Researchers are actively exploring strategies to modulate the immune response to oncolytic virotherapy, such as incorporating immunomodulatory agents to enhance anti-tumor immune responses or engineering viruses to evade immune detection. Achieving a delicate balance between exploiting the immune system's natural ability to fight cancer and overcoming potential barriers imposed by immune recognition is a critical aspect in the ongoing development and optimization of oncolytic virotherapy within the global market. Addressing these immunological challenges is fundamental to ensuring the safety, efficacy, and durability of oncolytic virotherapy as a viable treatment option for diverse cancer types.

Key Market Trends

Focus on Personalized Medicine

The Global Oncolytic Virotherapy Market has been witnessing a notable trend towards a more personalized approach to cancer treatment, marking a paradigm shift in the landscape of oncology. The focus on personalized medicine within the oncolytic virotherapy domain is driven by an increasing understanding of the intricate molecular and genetic characteristics of individual tumors. Researchers and clinicians are leveraging this knowledge to tailor oncolytic virotherapy to the unique profile of each patient's cancer, optimizing treatment outcomes. Advancements in cancer genomics have enabled a deeper understanding of the genetic mutations and alterations that drive tumor growth. This wealth of information allows for the identification of specific vulnerabilities within cancer cells, which can be targeted by oncolytic viruses. By tailoring these viruses to exploit the distinct genetic features of individual tumors, personalized oncolytic virotherapy holds the promise of heightened efficacy and reduced side effects compared to traditional, one-size-fits-all treatments. Furthermore, the trend towards personalized medicine aligns with the broader shift towards precision oncology. The integration of molecular diagnostics and genomic profiling in the clinical decision-making process allows oncologists to select the most appropriate oncolytic viruses for each patient, increasing the likelihood of a positive response. This tailored approach is particularly relevant in addressing the inherent heterogeneity among different cancer types and even within tumors of the same type. The move towards personalized oncolytic virotherapy is not only driven by advancements in genomic research but also by the growing availability of technologies that facilitate the rapid and cost-effective analysis of patients' genetic information. As the field continues to evolve, the focus on personalized medicine in oncolytic virotherapy is expected to be a key driver, shaping the future of cancer treatment by delivering more effective and targeted therapies tailored to the individual characteristics of each patient's cancer.

Clinical Advancements

Clinical advancements in the Global Oncolytic Virotherapy Market have been pivotal in reshaping the landscape of cancer treatment. With an increasing emphasis on translating laboratory discoveries into real-world applications, the market has witnessed a surge in clinical trials exploring the safety, efficacy, and potential of oncolytic viruses across diverse cancer types. These trials have not only demonstrated the feasibility of oncolytic virotherapy but have also provided valuable insights into its mechanisms of action and optimal application. Positive outcomes from clinical trials have instilled confidence in the viability of oncolytic virotherapy as a mainstream cancer treatment. The data generated from these trials have helped refine treatment protocols, identify patient populations most likely to benefit, and establish safety profiles, addressing key concerns in the broader medical community. The evolving clinical landscape has seen oncolytic virotherapy transition from experimental interventions to potential candidates for standard-of-care protocols in certain cancer indications. Moreover, ongoing clinical advancements have allowed researchers to explore combination therapies, integrating oncolytic virotherapy with other modalities such as immunotherapy, chemotherapy, and targeted therapies. The synergistic effects observed in these combinations hold promise for enhanced treatment outcomes and prolonged patient survival. This approach aligns with the broader trend in oncology towards combination therapies that leverage the strengths of different treatment modalities. The clinical advancements in the oncolytic virotherapy market have also facilitated the identification of optimal delivery methods, dosages, and treatment schedules. These refinements contribute to the overall maturation of oncolytic virotherapy as a therapeutic option that can be effectively integrated into existing cancer treatment paradigms. As the momentum of clinical advancements in oncolytic virotherapy continues, it is expected to drive regulatory approvals, market penetration, and the establishment of oncolytic viruses as valuable tools in the oncologist's arsenal, ultimately improving patient outcomes in the global fight against cancer.

Segmental Insights

Virus Type Insights

Based on virus type, genetically engineered oncolytic virus segment dominated the Global Oncolytic Virotherapy Market in 2023. This is ascribed due to rising demand for targeted treatments like adenovirus-based virotherapy, renowned for their precision in gene delivery, is propelling significant market expansion. This surge is driven by the ability of adenoviruses to precisely target specific regions, boosting their market share. In response to this trend, companies are proactively engaging in collaborations and strategic agreements to augment their market presence. These collaborative efforts are aimed at fostering innovation, advancing research, and accelerating the development of adenovirus-based virotherapy, reflecting the dynamic and competitive nature of this evolving segment within the broader therapeutic landscape.

Application Insights

Based on application, lung cancer segment dominated the Global Oncolytic Virotherapy Market in 2023. This is ascribed due to the high incidence of lung cancer globally. Given the pressing need for effective treatments, oncolytic virotherapy, with its targeted approach, has gained prominence in lung cancer management. Clinical advancements and positive outcomes in trials have further fueled its adoption. Additionally, increased research focus and strategic collaborations specifically tailored to address lung cancer challenges have propelled oncolytic virotherapy as a significant and promising therapeutic option within the oncology landscape.

Regional Insights

North America holds the largest share in the Global Oncolytic Virotherapy Market due to due to robust research infrastructure, substantial investment in healthcare, and early adoption of innovative therapies. Leading pharmaceutical companies, academic institutions, and research centers in North America actively contribute to the development and commercialization of oncolytic virotherapy. Additionally, favorable regulatory frameworks and a high prevalence of cancer cases in the region have accelerated the market's growth. The region's advanced healthcare ecosystem and proactive approach to novel treatments have positioned North America as a key player, driving the dominance of oncolytic virotherapy in this market.

Key Market Players

Novartis AG

Pfizer Inc.

GlaxoSmithKline plc

Immunocore Holdings plc.

F. Hoffmann-La Roche Ltd.

AstraZeneca

Merck & Co., Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Johnson & Johnson Services, Inc.

Report Scope:

In this report, the Global Oncolytic Virotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncolytic Virotherapy Market, By Virus Type:

Genetically Engineered Oncolytic Virus Oncolytic Wild Type Virus

Oncolytic Virotherapy Market, By Application:

Lung Cancer Breast Cancer Colorectal Cancer Melanoma Prostate Cancer Head and Neck Cancer Ovarian Cancer Pancreatic Cancer Others

Oncolytic Virotherapy Market, By End User:

Hospitals & Clinics Cancer Research Centers Others

Oncolytic Virotherapy Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Oncolytic Virotherapy Market.

Available Customizations:

Global Oncolytic Virotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncolytic Virotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Virus Type (Genetically Engineered Oncolytic Virus, Oncolytic Wild Type Virus)
  • 5.2.2. By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Cancer Research Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Virus Type
  • 5.3.2. By Application
  • 5.3.3. By End User
  • 5.3.4. By Region

6. Asia Pacific Oncolytic Virotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Virus Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Oncolytic Virotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Virus Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. India Oncolytic Virotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Virus Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Oncolytic Virotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Virus Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Oncolytic Virotherapy Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Virus Type
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Oncolytic Virotherapy Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Virus Type
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By End User

7. Europe Oncolytic Virotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Virus Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Oncolytic Virotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Virus Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Oncolytic Virotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Virus Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Oncolytic Virotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Virus Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Oncolytic Virotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Virus Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Oncolytic Virotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Virus Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. North America Oncolytic Virotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Virus Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Oncolytic Virotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Virus Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Oncolytic Virotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Virus Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Oncolytic Virotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Virus Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User

9. South America Oncolytic Virotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Virus Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Oncolytic Virotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Virus Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Oncolytic Virotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Virus Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Oncolytic Virotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Virus Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Oncolytic Virotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Virus Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Oncolytic Virotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Virus Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Oncolytic Virotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Virus Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Oncolytic Virotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Virus Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User
  • 10.3.4. Egypt Oncolytic Virotherapy Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Virus Type
      • 10.3.4.2.2. By Application
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Oncolytic Virotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. GlaxoSmithKline plc
• 15.4. Immunocore Holdings plc
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. AstraZeneca
• 15.7. Merck & Co., Inc.
• 15.8. Boehringer Ingelheim GmbH
• 15.9. Bristol-Myers Squibb Company
• 15.10. Johnson & Johnson Services, Inc

16. Strategic Recommendations

17. About Us & Disclaimer